- Tytuł:
- A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study
- Autorzy:
- Źródło:
- In ESMO Open October 2021 6(5)
Czasopismo naukowe